|
During the course of his career, Dr. Kumar has held roles of increasing responsibility in small-to-medium-to-large pharmaceutical companies including Pfizer, Pharmacia Corporation and OSI Pharmaceuticals. He has relentlessly pursued excellence in proposing new ideas and developing new hypotheses to discover and develop innovative drugs for metabolic diseases and chronic inflammatory diseases. Dr. Kumar has served as either a project leader or co-project leader of several drug discovery and development projects in Type II Diabetes, Atherosclerosis, Obesity, and Chronic Inflammatory Diseases. Some of the projects include: 'beta-cell centric' therapies, inhibitors of insulin-dependent hepatic gluconeogenesis, incretin mimetics, PPAR agonists, CRF-2R activators, activators of ApoA1, inhibitors of apo(a), inhibitors of Scavenger receptor, inhibitors of TNF-alpha, inhibitors of mPGES-1 (safer Celebrex™), TLR4 blockers, inhibitors of iNOS, FXR activators etc.
He obtained M.S. and Ph.D. in Molecular and Cell Biology from New York University, an executive Mini-MBA in Bio-Pharma Innovation from Rutgers University, and a certification for GCP (Good Clinical Practice) from ACRP (Association of Clinical Research Professionals). Prior to his 25 year career in the pharmaceutical industry, Dr. Kumar was a Research Fellow at The Cleveland Clinic Foundation, Cleveland, OH.
|
